BioNTech Shares Drop After Colorectal Cancer Vaccine Trial Fails
BioNTech (NASDAQ:BNTX) shares fell nearly 8% after the company announced it had terminated its Phase 2 colorectal cancer vaccine trial due to futility. The decision followed a recommendation from an independent Data Safety Monitoring Board, which noted no significant improvement in overall survival between treatment arms. Moderna (NASDAQ:MRNA), a peer in mRNA-based oncology research, also dropped by about 6%, while Pfizer (NYSE:PFE) remained relatively stable at -0.4%. The market reaction appears to be specific to the biotech sector rather than signaling broader economic concerns. The failed trial involved BioNTech's autogene cevumeran vaccine in collaboration with Genentech, targeting high-risk Stage II/III colorectal cancer patients post-surgery. Despite earlier optimism and a 17% year-to-date rise in shares, the setback has raised questions about the viability of mRNA vaccines for immunologically cold tumors like colorectal cancer. In contrast to BioNTech's monotherapy approach, Moderna recently reported success with its melanoma vaccine combined with Keytruda. However, investors are now re-evaluating the broader potential of mRNA-based oncology treatments in light of these divergent outcomes.
Topics: biotech colorectal cancer mRNA vaccines stock market reaction